1 Key Insights

2 Report Introduction

3 Asthma Market Overview at a Glance

3.1 Market Share (%) Distribution of Asthma in 2020

3.2 Market Share (%) Distribution of Asthma in 2034

4 Methodology of Asthma Epidemiology and Market

5 Executive Summary of Asthma

6 Key Events

7 Disease Background and Overview

7.1 Introduction of Asthma

7.2 Classification of Asthma

7.3 Signs and Symptoms of Asthma

7.4 Causes of Asthma

7.5 Pathophysiology of Asthma

7.6 Diagnosis of Asthma

7.6.1 Diagnostic algorithm

7.6.2 Diagnostic guidelines

7.6.2.1 NICE Recommendations for Asthma Diagnosis

7.6.2.2 British Guidelines on the Diagnosis of Asthma

7.7 Treatment and Management of Asthma

7.7.1 Asthma Treatment algorithm

7.7.2 Asthma Treatment guidelines

7.7.2.1 NICE Recommendations for Asthma Management

7.7.2.2 British Guidelines on the Management of Asthma

7.7.2.3 International ERS/ATS Guidelines on the Definition, Evaluation, and Treatment of Severe Asthma

7.7.2.4 National Asthma Education and Prevention Program (NAEPP) Guidelines for Asthma

7.7.2.5 Global Initiative for Asthma – Global Strategy for Asthma Management and Prevention 2022

7.7.2.6 Japanese Guideline for Childhood Asthma (JGCA)

7.7.2.7 Japanese Guidelines for Adult Asthma 2020

8 Epidemiology and Patient Population

8.1 Key Findings

8.2 Assumptions and Rationale: The 7MM

8.2.1 Diagnosed prevalent cases of Asthma

8.2.2 Severity-specific cases of Asthma

8.2.3 Type-specific cases of severe Asthma

8.3 Total Diagnosed Prevalent Cases of Asthma in the 7MM

8.4 Age-specific Diagnosed Prevalent Cases of Asthma in the 7MM

8.5 The United States

8.5.1 Total diagnosed prevalent cases of Asthma in the US

8.5.2 Age-specific diagnosed prevalent cases of Asthma in the US

8.5.3 Gender-specific diagnosed prevalent cases of Asthma in the US

8.5.4 Severity-specific diagnosed prevalent cases of Asthma in the US

8.5.5 Type-specific severity diagnosed prevalent cases of Asthma in the US

8.6 EU4 and the UK

8.6.1. Germany

8.6.1.1 Total diagnosed prevalent cases of Asthma

8.6.1.2 Age-specific diagnosed prevalent cases of Asthma

8.6.1.3 Gender-specific diagnosed prevalent cases of Asthma

8.6.1.4 Severity-specific diagnosed prevalent cases of Asthma

8.6.1.5 Type-specific severity diagnosed prevalent cases of Asthma

8.6.2. France

8.6.2.1 Total diagnosed prevalent cases of Asthma

8.6.2.2 Age-specific diagnosed prevalent cases of Asthma

8.6.2.3 Gender-specific diagnosed prevalent cases of Asthma

8.6.2.4 Severity-specific diagnosed prevalent cases of Asthma

8.6.2.5 Type-specific severity diagnosed prevalent cases of Asthma

8.6.3. Italy

8.6.3.1 Total diagnosed prevalent cases of Asthma

8.6.3.2 Age-specific diagnosed prevalent cases of Asthma

8.6.3.3 Gender-specific diagnosed prevalent cases of Asthma

8.6.3.4 Severity-specific diagnosed prevalent cases of Asthma

8.6.3.5 Type-specific severity diagnosed prevalent cases of Asthma

8.6.4. Spain

8.6.4.1 Total diagnosed prevalent cases of Asthma

8.6.4.2 Age-specific diagnosed prevalent cases of Asthma

8.6.4.3 Gender-specific diagnosed prevalent cases of Asthma

8.6.4.4 Severity-specific diagnosed prevalent cases of Asthma

8.6.4.5 Type-specific severity diagnosed prevalent cases of Asthma

8.6.5. The UK

8.6.5.1 Total diagnosed prevalent cases of Asthma

8.6.5.2 Age-specific diagnosed prevalent cases of Asthma

8.6.5.3 Gender-specific diagnosed prevalent cases of Asthma

8.6.5.4 Severity-specific diagnosed prevalent cases of Asthma

8.6.5.5 Type-specific severity diagnosed prevalent cases of Asthma

8.7 Japan

8.7.1 Total diagnosed prevalent cases of Asthma in Japan

8.7.2 Age-specific diagnosed prevalent cases of Asthma in Japan

8.7.3 Gender-specific diagnosed prevalent cases of Asthma in Japan

8.7.4 Severity-specific diagnosed prevalent cases of Asthma in Japan

8.7.5 Type-specific severity diagnosed prevalent cases of Asthma in Japan

9 Asthma Patient Journey

10 Asthma Marketed Therapies

10.1 Key Cross Competition

10.2 TEZSPIRE (tezepelumab-ekko): Amgen/AstraZeneca

10.2.1 Product description

10.2.2 Regulatory milestones

10.2.3 Other development activities

10.2.4 Clinical development

10.2.5 Clinical trials information

10.2.6 Safety and efficacy

10.2.7 Product profile

10.3 TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol): GlaxoSmithKline

10.3.1 Product description

10.3.2 Regulatory milestones

10.3.3 Other development activities

10.3.4 Clinical development

10.3.5 Clinical trials information

10.3.6 Safety and efficacy

10.3.7 Product profile

10.4 ARNUITY ELLIPTA (fluticasone furoate inhalation powder): GlaxoSmithKline

10.4.1 Product description

10.4.2 Regulatory milestones

10.4.3 Other Development activities

10.4.4 Clinical trials information

10.4.5 Safety and efficacy

10.4.6 Product profile

10.5 CINQAIR (reslizumab): Teva Pharmaceutical

10.5.1 Product description

10.5.2 Regulatory milestones

10.5.3 Other development activities

10.5.4 Clinical development

10.5.5 Clinical Trial Information

10.5.6 Safety and efficacy

10.5.7 Product profile

10.6 FASENRA (benralizumab): AstraZeneca

10.6.1 Product description

10.6.2 Regulatory milestone

10.6.3 Other development activities

10.6.4 Clinical development

10.6.5 Clinical Trial Information

10.6.6 Safety and efficacy

10.6.7 Product profile

10.7 DUPIXENT (dupilumab): Sanofi and Regeneron Pharmaceutical

10.7.1 Product description

10.7.2 Regulatory milestones

10.7.3 Other development activities

10.7.4 Clinical development

10.7.5 Clinical trial information

10.7.6 Safety and efficacy

10.7.7 Product profile

10.8 NUCALA (mepolizumab): GlaxoSmithKline (GSK)

10.8.1 Product description

10.8.2 Regulatory milestones

10.8.3 Other development activities

10.8.4 Clinical development

10.8.5 Clinical trial information

10.8.6 Safety and efficacy

10.8.7 Product profile

10.9 AIRSUPRA (albuterol and budesonide): AstraZeneca/Avillion

10.9.1 Product description

10.9.2 Regulatory milestones

10.9.3 Other development activities

10.9.4 Clinical development

10.9.5 Clinical trials information

10.9.6 Safety and efficacy

10.9.7 Product profile

10.10 XOLAIR (omalizumab): Novartis

10.10.1 Product description

10.10.2 Regulatory milestone

10.10.3 Other development activities

10.10.4 Clinical trial information

10.10.5 Safety and efficacy

10.10.6 Product profile

10.11 Enerzair Breezhaler (indacaterol/glycopyrronium bromide/mometasone): Novartis

10.11.1 Product description

10.11.2 Regulatory milestone

10.11.3 Other development activities

10.11.4 Clinical development

10.11.5 Clinical trial information

10.11.6 Safety and efficacy

10.11.7 Product profile

10.12 Atectura Breezhaler (indacaterol/mometasone): Novartis

10.12.1 Product description

10.12.2 Regulatory milestone

10.12.3 Clinical development

10.12.4 Clinical trial information

10.12.5 Safety and efficacy

10.12.6 Product profile

10.13 TRIMBOW (beclometasone/formoterol/glycopyrronium): Chiesi Farmaceutici

10.13.1 Product description

10.13.2 Regulatory milestone

10.13.3 Other development activities

10.13.4 Clinical trial information

10.13.5 Safety and efficacy

10.13.6 Product profile

10.14 Spiriva Respimat (tiotropium): Boehringer Ingelheim Pharmaceuticals

10.14.1 Product description

10.14.2 Regulatory milestone

10.14.3 Other development activities

10.14.4 Clinical trial information

10.14.5 Safety and efficacy

10.14.6 Product profile

11 Emerging Therapies

11.1 Key Cross Competition

11.2 GSK3511294 (Depemokimab): GlaxoSmithKline

11.2.1 Product description

11.2.2 Clinical development

11.2.3 Clinical trial information

11.2.4 Safety and efficacy

11.2.5 Product profile

11.2.6 Analyst’s views

11.3 Masitinib (AB07105): AB Science

11.3.1 Product description

11.3.2 Other development activities

11.3.3 Clinical development

11.3.4 Clinical trial information

11.3.5 Safety and efficacy

11.3.6 Product profile

11.3.7 Analyst’s views

11.4 PT010: AstraZeneca

11.4.1 Product description

11.4.2 Clinical development

11.4.3 Clinical trials information

11.4.4 Product profile

11.4.5 Analyst’s views

11.5 Dexpramipexole Dihydrochloride: Areteia Therapeutics

11.5.1 Product description

11.5.2 Other development activities

11.5.3 Clinical development

11.5.4 Clinical trial information

11.5.5 Safety and efficacy

11.5.6 Product profile

11.5.7 Analyst’s views

11.6 PBF-680: Palobiofarma SL/Pivotal S.L.

11.6.1 Product description

11.6.2 Other development activities

11.6.3 Clinical development

11.6.4 Clinical trial information

11.6.5 Safety and efficacy

11.6.6 Product profile

11.7 ARS 1: ARS Pharmaceuticals, Inc.

11.7.1 Product description

11.7.2 Other development activities

11.7.3 Clinical development

11.7.4 Clinical trial information

11.7.5 Product profile

11.8 MEDI3506 (tozorakimab): AstraZeneca

11.8.1 Product description

11.8.2 Clinical development

11.8.3 Clinical trials information

11.8.4 Safety and efficacy

11.8.5 Product profile

11.8.6 Analyst’s views

11.9 AZD1402 (PRS-060): Pieris Pharma/AstraZeneca

11.9.1 Product description

11.9.2 Other development

11.9.3 Clinical development

11.9.4 Clinical trials information

11.9.5 Product profile

11.9.6 Analyst’s views

11.10 Atuliflapon (AZD5718): AstraZeneca

11.10.1 Product description

11.10.2 Clinical development

11.10.3 Clinical trials information

11.10.4 Product profile

11.11 Amlitelimab: Sanofi

11.11.1 Product description

11.11.2 Other development activities

11.11.3 Clinical development

11.11.4 Clinical trials information

11.11.5 Product profile

11.12 Rilzabrutinib: Sanofi

11.12.1 Product description

11.12.2 Other development activities

11.12.3 Clinical development

11.12.4 Clinical trial information

11.12.5 Product profile

11.13 BOXABAN (Ifetroban): Cumberland Pharmaceuticals

11.13.1 Product description

11.13.2 Other development activities

11.13.3 Clinical development

11.13.4 Clinical trial information

11.13.5 Safety and efficacy

11.13.6 Product profile

11.14 RG6341 (GDC-6599): Genentech Research/Roche

11.14.1 Product description

11.14.2 Clinical development

11.14.3 Clinical trial information

11.14.4 Product profile

11.15 CBP-201: Suzhou Connect Biopharmaceuticals

11.15.1 Product description

11.15.2 Other development activities

11.15.3 Clinical development

11.15.4 Clinical trial information

11.15.5 Product profile

11.15.6 Analyst’s views

11.16 AVTX-002 (Quisovalimab): Avalo Therapeutics

11.16.1 Product description

11.16.2 Other development activities

11.16.3 Clinical development

11.16.4 Clinical trial information

11.16.5 Product profile

11.16.6 Analyst’s views

11.17 MRx-4DP0004: 4D Pharma plc

11.17.1 Product description

11.17.2 Clinical development

11.17.3 Clinical trial information

11.17.4 Safety and efficacy

11.17.5 Product profile

11.17.6 Analyst’s views

11.18 SB010: Sterna Biologicals

11.18.1 Product description

11.18.2 Other Development activities

11.18.3 Clinical development

11.18.4 Clinical trial information

11.18.5 Safety and efficacy

11.18.6 Product profile

11.18.7 Analyst’s views

12 Asthma: Market Analysis

12.1 Key Findings

12.2 Key Market Forecast Assumptions

12.3 Market Outlook

12.4 Attribute Analysis

12.5 Total Market Size of Asthma in the 7MM

12.6 Total Market Size of Asthma by Therapies in the 7MM

12.7 Market Size of Asthma in the US

12.7.1 Total market size of Asthma

12.7.2 The market size of Asthma by therapies

12.8 Market Size of Asthma in EU4 and the UK

12.8.1 Germany

12.8.1.1 Total market size of Asthma

12.8.1.2 The market size of Asthma by therapies

12.8.2 France

12.8.2.1 Total market size of Asthma

12.8.2.2 The market size of Asthma by therapies

12.8.3 Italy

12.8.3.1 Total market size of Asthma

12.8.3.2 The market size of Asthma by therapies

12.8.4 Spain

12.8.4.1 Total market size of Asthma

12.8.4.2 The market size of Asthma by therapies

12.8.5 The UK

12.8.5.1 Total market size of Asthma

12.8.5.2 The market size of Asthma by therapies

12.9 Market Size of Asthma in Japan

12.9.1 Total market size of Asthma

12.9.2 The market size of Asthma by therapies

13 KOL Views

14 SWOT Analysis

15 Unmet needs

16 Market Access and Reimbursement

16.1 The United States

16.1.1 Centre for Medicare & Medicaid Services (CMS)

16.2 In EU4 and the UK

16.2.1 Germany

16.2.2 France

16.2.3 Italy

16.2.4 Spain

16.2.5 The United Kingdom

16.3 Japan

16.3.1 MHLW

17 Appendix

17.1 Bibliography

17.2 Acronyms and Abbreviations

17.3 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer